[B或浆细胞定向嵌合抗原受体T细胞疗法中HBV再激活的预防和治疗共识（2021年）] - Suppr

Suppr

超能文献

[The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)].

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2021 Jun 14;42(6):441-446. doi: 10.3760/cma.j.issn.0253-2727.2021.06.001.

DOI:10.3760/cma.j.issn.0253-2727.2021.06.001

PMID:34384148

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8295609/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/887b/8295609/8cd7fb3fad87/cjh-42-06-441-g001.jpg

相似文献

[The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)].[B或浆细胞定向嵌合抗原受体T细胞疗法中HBV再激活的预防和治疗共识（2021年）]

Zhonghua Xue Ye Xue Za Zhi. 2021 Jun 14;42(6):441-446. doi: 10.3760/cma.j.issn.0253-2727.2021.06.001.

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.未行抗病毒预防的接受抗 CD19 嵌合抗原受体 T 细胞治疗的乙型肝炎病毒（HBV）感染已缓解患者的 HBV 再激活风险。

Front Immunol. 2021 Jul 15;12:638678. doi: 10.3389/fimmu.2021.638678. eCollection 2021.

Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.嵌合抗原受体-T 细胞治疗人源化抗 CD19 对慢性和已解决乙型肝炎病毒感染的淋巴瘤和白血病患者安全且有效。

Hematol Oncol. 2021 Feb;39(1):75-86. doi: 10.1002/hon.2807. Epub 2020 Oct 1.

Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy.病例报告：尽管使用恩替卡韦进行预防治疗，两名淋巴瘤患者在接受 CAR-T 输注后仍出现 HBV 再激活。

Front Immunol. 2021 Oct 8;12:751754. doi: 10.3389/fimmu.2021.751754. eCollection 2021.

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.癌症患者在接受 PD-1 抑制治疗时，若乙型肝炎表面抗原阳性，则可能会出现乙型肝炎病毒再激活。

J Immunother Cancer. 2019 Nov 21;7(1):322. doi: 10.1186/s40425-019-0808-5.

Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.嵌合抗原受体 (CAR)-T 细胞疗法在患有晚期 B 细胞癌症和乙型肝炎病毒感染的人群中的安全性和有效性。

Leukemia. 2020 Oct;34(10):2704-2707. doi: 10.1038/s41375-020-0936-4. Epub 2020 Jun 27.

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.接受抗 CD19 和抗 CD22 CAR T 细胞治疗弥漫性大 B 细胞淋巴瘤的患者发生严重早期乙型肝炎病毒再激活。

J Immunother Cancer. 2019 Nov 21;7(1):315. doi: 10.1186/s40425-019-0790-y.

CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells.经单细胞分选鉴定的广泛中和性人源单克隆抗体衍生的嵌合受体可靶向乙型肝炎病毒阳性细胞。

Front Immunol. 2024 Apr 22;15:1340619. doi: 10.3389/fimmu.2024.1340619. eCollection 2024.

Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model.评估一种在免疫功能正常的小鼠模型中具有乙肝病毒特异性的嵌合抗原受体。

Mol Ther. 2019 May 8;27(5):947-959. doi: 10.1016/j.ymthe.2019.02.001. Epub 2019 Feb 10.

Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy.接受抗B细胞治疗患者的乙型肝炎病毒再激活的筛查与管理

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):576-83. doi: 10.1182/asheducation-2014.1.576. Epub 2014 Nov 18.

引用本文的文献

Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.嵌合抗原受体 T 细胞疗法治疗不同 HBV 状态的复发/难治性弥漫性大 B 细胞淋巴瘤的疗效和安全性：来自单个中心的回顾性研究。

Front Immunol. 2023 May 24;14:1200748. doi: 10.3389/fimmu.2023.1200748. eCollection 2023.

Long-Term Safety of Rituximab in DLBCL Patients With Hepatitis B-Related Cirrhosis: A Retrospective Case Series.利妥昔单抗在乙型肝炎相关肝硬化的弥漫性大B细胞淋巴瘤患者中的长期安全性：一项回顾性病例系列研究

Front Med (Lausanne). 2022 May 30;9:890339. doi: 10.3389/fmed.2022.890339. eCollection 2022.

Front Immunol. 2021 Oct 8;12:751754. doi: 10.3389/fimmu.2021.751754. eCollection 2021.

本文引用的文献

Hematol Oncol. 2021 Feb;39(1):75-86. doi: 10.1002/hon.2807. Epub 2020 Oct 1.

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus.嵌合抗原受体 T 细胞靶向 BCMA 治疗多发性骨髓瘤合并慢性乙型肝炎病毒感染患者的安全性和有效性。

J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-000927.

Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.癌症患者治疗前的乙型肝炎病毒筛查和管理：ASCO 临时临床意见更新。

J Clin Oncol. 2020 Nov 1;38(31):3698-3715. doi: 10.1200/JCO.20.01757. Epub 2020 Jul 27.

Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy.接受抗CD19嵌合抗原受体T细胞疗法的B细胞淋巴瘤患者中，乙肝病毒再激活的风险是可控的。

Br J Haematol. 2020 Oct;191(1):126-129. doi: 10.1111/bjh.16951. Epub 2020 Jul 15.

The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection.嵌合抗原受体T细胞（CAR-T）疗法在难治性急性淋巴细胞白血病（ALL）合并乙肝病毒（HBV）感染患者中的疗效和安全性。

Leukemia. 2020 Oct;34(10):2790-2793. doi: 10.1038/s41375-020-0952-4. Epub 2020 Jul 6.

Leukemia. 2020 Oct;34(10):2704-2707. doi: 10.1038/s41375-020-0936-4. Epub 2020 Jun 27.

Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.弥漫性大B细胞淋巴瘤（DLBCL）合并慢性乙型肝炎病毒（HBV）感染患者接受CD19嵌合抗原受体T细胞（CAR-T）治疗后HBV再激活的风险

Leukemia. 2020 Nov;34(11):3055-3059. doi: 10.1038/s41375-020-0913-y. Epub 2020 Jun 12.

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy.恩替卡韦预防接受嵌合抗原受体T细胞（CAR T）治疗患者的乙型肝炎病毒再激活

Blood. 2020 Jul 23;136(4):516-519. doi: 10.1182/blood.2020004907.

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30 lymphoma patients.抗CD30嵌合抗原受体T细胞疗法用于复发/难治性CD30淋巴瘤患者。

Blood Cancer J. 2020 Jan 23;10(1):8. doi: 10.1038/s41408-020-0274-9.

[The guidelines of prevention and treatment for chronic hepatitis B (2019 version)].《慢性乙型肝炎防治指南（2019年版）》

Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):938-961. doi: 10.3760/cma.j.issn.1007-3418.2019.12.007.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验